65th ASH Annual Meeting & Exposition: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Biological therapies, Chimeric Antigen Receptor (CAR)-T Cell Therapies, immune mechanism, Therapies, Immunotherapy, immunology, Biological Processes, microbiome, pathogenesis

Harbor Ballroom (Manchester Grand Hyatt San Diego)

Moderators:

Francesca Cottini, MD, The Ohio State University Comprehensive Cancer Center and Nicola Giuliani, MD, PhD, University of Parma

Disclosures:

Cottini: The Dedham Group: Consultancy; Techspert Network: Consultancy. Giuliani: PFIZER: Research Funding; European Myeloma Network: Research Funding; AMGEN: Membership on an entity's Board of Directors or advisory committees; TAKEDA: Membership on an entity's Board of Directors or advisory committees; BRISTOL MAYERS SQUIBB: Consultancy; EFFETTI S.R.L: Other: PRECEPTORSHIP; ER CONGRESSI: Other: PRECEPTORSHIP; VYVAMED: Other: PRECEPTORSHIP; FIRST CLASS EVENTS 6 CONFERENCE: Other: PRECEPTORSHIP; PREX S.R.L.: Other: PRECEPTORSHIP; DYNAMICON EDUCATION S.R.L.: Other: PRECEPTORSHIP; RAY HEALTHCARE COMMUNICATION S.R.L.: Other: PRECEPTORSHIP.

This session is dedicated to advancing therapeutic strategies in the field of multiple myeloma and Waldenström's Macroglobulinemia. The session encompasses approaches to enhancing CAR T-cell tumor specificity, single-cell multi-omic analysis to identify novel mediators and therapeutic targets, the investigation of CRBN mutations and their impact on treatment response, the potential exploitation of gut microbiota to boost immunotherapy, and insights into methylation and chromatin accessibility for disease classification and evolution.

10:30 AM

751

And-Gate CAR T-Cells to Improve Tumour Specificity and Targeting of Low-Expression Antigens in Multiple Myeloma

Georgina S.F. Anderson, PhD¹^*, Ieuan Walker, MBBS, MSc, BSc, MRCP², James P Roy, PhD²^* and Michael A. Chapman, MD PhD^2,3

¹MRC Toxicology Unit, University of Cambridge, Cambridge, ENG, United Kingdom
²MRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom
³Department of Haematology, University of Cambridge, Cambridge, United Kingdom

10:45 AM

752

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Luz Yurany Moreno Rueda, PhD, MSc¹^*, Keiko Akagi, PhD²^*, Amishi U. Vora, BS¹^*, Hans Lee, MD¹, Krina K. Patel, MD, MSc³, Pei Lin, MD, DM, MDPC⁴, Bo Jiang, BS²^*, Yang Song, PhD¹^*, Maura L. Gillison, MD, PhD²^*, Sheeba K. Thomas, MD¹, Donna M. Weber, MD¹, Lixia Diao, PhD⁵^*, Jing Wang, PhD⁵^*, Elisabet E. Manasanch, MD¹, David E. Symer, MD, PhD¹ and Robert Z. Orlowski, MD, PhD^1,6

¹Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Thoracic-Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
³University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX

11:00 AM

753

Investigating the Functional Impact of CRBN Mutations on Response to IMiD/Celmod Agents in Myeloma

Yakinthi Chrisochoidou, PhD¹^*, Yann-Vai LeBihan, PhD¹^*, Salomon Morales, MSc¹^*, Shannon Martin, MSc¹^*, Brian A. Walker, PhD², Yigen Li, PhD¹^*, Sarah Bird, BMBCh¹^* and Charlotte Pawlyn, MBBChir, PhD^1,3

¹The Institute of Cancer Research, London, United Kingdom
²Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN
³The Royal Marsden NHS Foundation Trust, London, United Kingdom

11:15 AM

754

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma

Laura Lucia Cogrossi^1,2^*, Matteo Grioni¹^*, Paola Zordan¹^*, Benedetta Mattorre¹^*, Marco Lorenzoni¹^*, Greta Meregalli¹^*, Anna Policastro^1,2^*, Roberto Ferrarese¹^*, Nicola Clementi^2,3^*, Sofia Sisti^2,3^*, Nicasio Mancini⁴^*, Marta Chesi, PhD⁵, P. Leif Bergsagel, MD⁵ and Matteo Bellone¹^*

¹Cellular immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano, Italy
²Vita-Salute San Raffaele University, Milano, Italy
³Laboratory of Microbiology, IRCCS Ospedale San Raffaele, Milano, Italy
⁴Insubria University, Varese, Italy
⁵Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ

11:30 AM

755

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström’s Macroglobulinemia

Zachary R Hunter, PhD¹, Nickolas Tsakmaklis, BA¹^*, Kris Richardson, PhD¹^*, Maria Luisa Guerrera, MD¹, Amanda Kofides¹^*, Xia Liu, MD¹^*, Shirong Liu, MD, PhD¹^*, Catherine A. Flynn, NP¹^*, Kirsten Meid, MPH¹^*, Christopher J Patterson¹^*, Mariateresa Fulciniti, PhD², Mehmet K. Samur, PhD³, Kenneth C. Anderson, MD², Nikhil C Munshi, MD²^*, Shayna R Sarosiek¹, Jorge J. Castillo, MD¹, Ari M Melnick, MD⁴ and Steven P. Treon, MD, PhD, FRCP¹

¹Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, MA
²Dana-Farber Cancer Institute, Harvard Medical School, The Jerome Lipper Multiple Myeloma Center, Boston, MA
³Dana-Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Boston, MA
⁴Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY

11:45 AM

756

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom’s Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Zachary R Hunter, PhD¹, Maria Luisa Guerrera, MD¹, Ruben D. Carrasco, MD, PhD²^*, Nickolas Tsakmaklis, BA¹^*, Kris Richardson, PhD¹^*, Amanda Kofides¹^*, Xia Liu, MD¹^*, Shirong Liu, MD, PhD¹^*, Catherine A. Flynn, NP¹^*, Kirsten Meid, MPH¹^*, Joshua Gustine, MD, MPH¹^*, Christopher J Patterson¹^*, Mariateresa Fulciniti, PhD³, Mehmet K. Samur, PhD⁴, Tomasz Sewastianik, MSc, PhD²^*, Kenneth C. Anderson, MD³, Nikhil C Munshi, MD³^*, Shayna R Sarosiek¹, Jorge J. Castillo, MD¹ and Steven P. Treon, MD, PhD, FRCP¹

¹Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, MA
²Dana-Farber Cancer Institute, Harvard Medical School, Department of Oncologic Pathology, Boston, MA
³Dana-Farber Cancer Institute, Harvard Medical School, The Jerome Lipper Multiple Myeloma Center, Boston, MA
⁴Dana-Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Boston, MA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651A.O3.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia